Humira provided faster and more complete clinical disease responses compared with methotrexate as treatment for plaque psoriasis, according to recently published study results. Researchers conducted ...
HUMIRA can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. HUMIRA has been shown to reduce the rate of progression of ...
HUMIRA can be used alone or in combination with methotrexate (MTX) or other disease-modifying anti-rheumatic drugs (DMARDs). HUMIRA is indicated for reducing signs and symptoms of moderately to ...
Bristol-Myers Squibb Company (NYSE: BMY) today announced the results of year two data from AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve rheumatoid arthritis (RA) Subjects With ...
The FDA has approved two new uses for the arthritis drug Humira. The drug, which was previously approved to treat rheumatoid arthritis in 2002, is now also approved to treat psoriatic arthritis, a ...
Please provide your email address to receive an email when new articles are posted on . Methotrexate increases the probability of remission with adalimumab or infliximab by 50% in patients with ...
AbbVie Announces Late-Breaking Results from Phase 3 Trial of HUMIRA® (adalimumab) in Hidradenitis Suppurativa (HS) Patients at the European Academy of Dermatology and Venereology Congress HS is a ...
man hands gout arthritis The trial compares short- and long-term outcomes of Cimzia and Humira in RA WASHINGTON, DC—Data from a head-to-head superiority trial comparing Cimzia (certolizumab pegol) and ...
Xeljanz and Xeljanz XR are Janus kinase (JAK) inhibitors indicated to treat moderately to severely active rheumatoid arthritis when methotrexate therapy is inadequate. The non-inferiority study found ...
SAN DIEGO — Erinn Maury knew Remicade wasn't the right drug for Patti Schulte, a rheumatoid arthritis patient the physician saw at her Millersville, Maryland, practice. Schulte's swollen, painful ...
MONTREAL, Feb. 20, 2019 /CNW/ - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that Health Canada has approved HUMIRA® (adalimumab) for the treatment of ...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has voted to recommend marketing authorization for Imraldi (adalimumab, Samsung Bioepsis UK Limited) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback